Vnitr Lek 1995, 41(3):172-175

[Pharmacotherapy of hyperlipoproteinemia in view of the newest European and American recommendations].

R Ceska: III. interní klinika VFN a 1. LF UK, Praha.

UNLABELLED: Hyperlipoproteinaemias, in particular types associated with elevated levels of total and LDL-cholesterol and partly triacylglycerols (in particular in combination with reduced HDL-cholesterol), are one of the most serious risk factors of early manifestation of IHD and atherosclerosis at other sites. Their effective treatment is considered a rational procedure in preventive cardiology. Who should be treated, when and how? When deciding we have to combine two basic approaches. Every patient must be considered individually, on the other hand, it is necessary to respect some general recommendations. The most comprehensive view of the given problem will be found in the innovated recommendations of the EAS of 1992 and NCEP of 1993. They contain not only values of parameters of the lipid and lipoprotein metabolism where dietetic and pharmacological intervention should be provided but also target values which should be aimed for in these patients. Treatment of hyperlipoproteinaemias is comprehensive and comprises dietary and lifestyle provisions. In indicated cases increasingly pharmacotherapy is emphasized to which most of the presented paper is devoted. Pharmacotherapy of hyperlipoproteinaemias. Hypolipidaemic agents can be divided into several groups. 1) Drugs which affect above all cholesterol; 2) Drugs which affect cholesterol and triacylglycerols (HDL-CH); 3) Drugs used only on a small scale; 4) Dietetic preparations; 5) Oestrogens? and 6) a combination of two or more hypolipidaemic agents!!!
CONCLUSION: The author discusses the basic indications of different hypolipidaemic agents from the aspect of their effect, safety and tolerance.(ABSTRACT TRUNCATED AT 250 WORDS)